| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
|
Quarter Ended |
|
|
Six Months Ended |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
204,971 |
|
|
$ |
172,179 |
|
|
$ |
402,156 |
|
|
$ |
326,625 |
|
| Diagnostics and Genomics |
|
|
64,527 |
|
|
|
52,469 |
|
|
|
125,512 |
|
|
|
102,595 |
|
| Intersegment |
|
|
(222 |
) |
|
|
(395 |
) |
|
|
(673 |
) |
|
|
(768 |
) |
| Consolidated net sales |
|
$ |
269,276 |
|
|
$ |
224,253 |
|
|
$ |
526,995 |
|
|
$ |
428,452 |
|
| Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
93,281 |
|
|
$ |
80,453 |
|
|
$ |
183,381 |
|
|
$ |
150,803 |
|
| Diagnostics and Genomics |
|
|
10,880 |
|
|
|
8,107 |
|
|
|
18,344 |
|
|
|
16,781 |
|
| Segment operating income |
|
$ |
104,161 |
|
|
$ |
88,560 |
|
|
$ |
201,725 |
|
|
$ |
167,584 |
|
| Costs recognized on sale of acquired inventory |
|
|
(84 |
) |
|
|
(23 |
) |
|
|
(1,595 |
) |
|
|
(23 |
) |
| Amortization of acquisition related intangible assets |
|
|
(18,380 |
) |
|
|
(15,027 |
) |
|
|
(36,769 |
) |
|
|
(30,528 |
) |
| Impact of partially owned consolidated subsidiaries(1) |
|
|
(1,004 |
) |
|
|
(207 |
) |
|
|
(2,567 |
) |
|
|
(207 |
) |
| Acquisition related expenses |
|
|
13,262 |
|
|
|
(4,421 |
) |
|
|
15,618 |
|
|
|
(4,558 |
) |
| Eminence impairment |
|
|
(18,715 |
) |
|
|
- |
|
|
|
(18,715 |
) |
|
|
- |
|
| Stock based compensation, inclusive of employer taxes |
|
|
(14,815 |
) |
|
|
(16,225 |
) |
|
|
(28,675 |
) |
|
|
(29,557 |
) |
| Restructuring costs |
|
|
(743 |
) |
|
|
(142 |
) |
|
|
(1,928 |
) |
|
|
(142 |
) |
| Corporate general, selling, and administrative expenses |
|
|
(1,334 |
) |
|
|
(1,520 |
) |
|
|
(1,524 |
) |
|
|
(2,482 |
) |
| Consolidated operating income |
|
$ |
62,348 |
|
|
$ |
50,995 |
|
|
$ |
125,570 |
|
|
$ |
100,087 |
|
|